Santero Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Santero Therapeutics is a private, preclinical-stage biotech tackling a major unmet need in chronic bacterial infections. The company's innovative platform targets the RelA/SpoT homolog (RSH) enzymes, a master switch for bacterial dormancy, with two distinct mechanisms: direct bactericidal activity and resensitization of dormant bacteria to standard-of-care antibiotics. Its lead program is focused on non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa infection, a population with high morbidity and mortality, and it has broad potential across multiple chronic and acute refractory infections.

Infectious DiseaseCardiovascularMetabolic

Technology Platform

Small molecule platform targeting bacterial RelA/SpoT homolog (RSH) enzymes to disrupt bacterial dormancy (persistence). Offers two mechanisms: direct killing of dormant bacteria and resensitization of dormant bacteria to existing antibiotics.

Opportunities

The platform addresses the significant unmet need of bacterial persistence, a root cause of relapse in chronic infections that is distinct from antibiotic resistance.

Its lead in NCFB targets a severe patient subpopulation with high morbidity, and the broad conservation of the RSH target allows for expansion into multiple chronic (wound, orthopedic) and acute hospital infection indications.

Risk Factors

High scientific risk in validating a novel bacterial target and mechanism in humans.

Clinical development risk in complex chronic infection trials and potential difficulty demonstrating added benefit on top of new standard-of-care.

As a pre-revenue, private company, it faces significant funding and execution risk to reach key milestones.

Competitive Landscape

Competition includes the first approved NCFB therapy (an anti-inflammatory, not an antibacterial) and other companies exploring anti-persistence strategies. Santero's unique angle is its specific targeting of the RSH enzyme family with a dual-mechanism approach (killing and resensitization), positioning it as a potential first-in-class agent for bacterial persistence.

More companies in Small Molecule Drugs →More companies in Belgium →